[1]李庞敏,毛培军,黄 倩,等.胰岛素联合达格列净治疗2型糖尿病临床疗效分析[J].陕西医学杂志,2020,49(11):1499-1502.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.034]
　LI Pangmin,MAO Peijun,HUANG Qian,et al.The clinical effect of insulin combined with dapagliflozinin treatment of patients with type 2 diabetes mellitus[J].,2020,49(11):1499-1502.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.034]
点击复制

胰岛素联合达格列净治疗2型糖尿病临床疗效分析
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年11期
页码:
1499-1502
栏目:
药物与临床
出版日期:
2020-11-05

文章信息/Info

Title:
The clinical effect of insulin combined with dapagliflozinin treatment of patients with type 2 diabetes mellitus
作者:
李庞敏; 毛培军; 黄 倩; 王亚妮; 刘立栋; 刘春芳; 徐腊梅
空军第九八六医院内分泌科(西安 710054)
Author(s):
LI Pangmin; MAO Peijun; HUANG Qian; et al.
Department of Endocrinology,the 986 Hospital of Air Force(Xi'an 710054)
关键词:
2型糖尿病;  治疗;  达格列净;  胰岛素;  体质量指数;  血糖
Keywords:
Type 2 diabetes mellitus;  Therapy;  Dapagliflozin;  Insulin;  Body mass index;  Blood glucose
分类号:
R587.1
DOI:
DOI:10.3969/j.issn.1000-7377.2020.11.034
文献标志码:
A
摘要:
目的:探讨胰岛素治疗血糖控制不佳的2型糖尿病(T2DM)患者加用达格列净治疗后的效果及对代谢指标的影响。方法:收集使用胰岛素强化治疗后血糖控制仍不达标的2型糖尿病患者20例,胰岛素使用剂量大于60 U/d。口服达格列净片 10 mg,1次/d,并个体化给予减少胰岛素剂量治疗20周后,测量体质量、体质量指数(BMI)、低密度脂蛋白(LDL)、尿微量白蛋白、甘油三酯(TG)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、空腹血糖(FBG)、餐后2 h血糖(2hPG),记录胰岛素剂量,观察上述指标水平与服用达格列净前的基线水平比较变化情况。结果:加入达格列净治疗20周后,体质量、BMI、尿微量白蛋白、TC、TG、LDL、FBG、2hPG、胰岛素剂量均下降(P<0.05)。20例联合使用达格列净治疗的患者未出现泌尿系感染,3例患者使用初期有明显口干、多尿症状,未停药1周后口干、多尿症状逐渐消失。在结合血糖水平及时调整胰岛素剂量情况下,未出现低血糖事件。结论:在大剂量胰岛素治疗后血糖控制仍不达标的2型糖尿病患者,使用达格列净可减少胰岛素剂量,在控制血糖的同时降低体重,无明显低血糖风险,提示联合达格列净治疗方案优于单纯大剂量胰岛素治疗。
Abstract:
Objective:To analyze the effect of insulin combined with dapagliflozin in treatment of type 2 diabetes patients with poor blood glucose control and its effect on metabolic indexes.Methods:20 type 2 diabetes patients who had poor blood glucose control after receiving intensive insulin therapy were included.The insulin dose was more than 60 U/d.The body weight,BMI,TC,TG,LDL,urinary microalbumin,HbA1c,FBG,2hPG were measured and insulin dosage was recorded after taking dapagliflozin 10 mg orally once a day and individualized insulin dosage reduction for 20 weeks.The changes of the above indexes were compared with the baseline level before the administration of dapagliflozin.Results:After 20 weeks of dapagliflozin treatment,the body weight,BMI,urinary microalbumin,TC,TG,LDL,FBG,2hPG and insulin dosage were significantly decreased(P<0.05).There was no urinary tract infection in 20 patients treated with dapagliflozin.The symptoms of dry mouth and polyuria were obvious in 3 patients at the initial stage of use and disappeared gradually one week after the drug was not stopped.There was no hypoglycemic event when the insulin dosage was adjusted in time in combination with the blood glucose level.Conclusion:In type 2 diabetes patients who have poor blood glucose control after high-dose insulin treatment,dapagliflozin can significantly reduce the dosage of insulin,effectively control blood glucose and significantly reduce weight,with no significant risk of hypoglycemia.It is suggested that the combination of dapagliflozin therapy is superior to high dose insulin therapy.

参考文献/References:

[1] Cai X,Ji L,Chen Y,et al.Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients:a meta-analysis[J].J Diabetes Investig,2017,8(4):510-517.
[2] Baker WL,Buckley LF,Kelly MS,et al.Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure:a system aticreview and meta-analysis[J].J Am Heart Assoc,2017,6(5):5686.
[3] Mazidi M,Rezaie P,Gao HK,et al.Effect of sodium-glucose co transport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus:a systematic review and meta-analysis of 43 randomized control trials with 22528 patients[J].J Am Heart Assoc,2017,6:4007.
[4] Imprialos K,Faselis C,Boutari C,et al.SGLT-2 inhibitors and cardiovascular risk in diabetes mellitus:a comprehensive and critical review of the literature[J].Curr Pharm Des,2017,23(10):1510-1521.
[5] Dziuba J,Alperin P,Racketa J,et al.Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes[J].Diabetes Obes Metab,2014,16(70):628-635.
[6] Nauck MA.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes[J].Drug Des Devel Ther,2014,8:1335-1380.
[7] Tosaki T,Kamiya H,Himeno T,et al.Sodium-glucose cotransporter 2 inhibitors reduce the abdo minal visceral fatarea and may influence the renal functionin patients with type 2 diabetes[J].Intern Med,2017,56(6):597-604.
[8] Nishimura R,Tanaka Y,Koiwai K,et al.Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus:a randomized,double-blind,placebo-controlled,4-week study[J].Cardiovasc Diabetol,2015,14:11.
[9] Kashiwagi A,Kazuta K,Yoshida S,et al.Randomized,placebo-controlled,double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus[J].J Diabetes Investig,2014,5(4):382-391.
[10] Kaku K,Watada H,Iwamoto Y,et al.Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus:a combined phase 2 and 3 randomized,placebo-controlled,double-blind,parallel-group comparative study[J].Cardiovasc Diabetol,2014,13:65.
[11] 蒋建家,张雅萍,牟伦盼,等.达格列净对预混胰岛素治疗血糖控制不达标的2型糖尿病患者的疗效和安全性研究[J].中华糖尿病杂志,2018,26(12):993-996.
[12] 刘毅龙,陈鹏宇,雷 江,等.SGLT-2 抑制剂在2 型糖尿病合并心血管疾病治疗中的应用研究进展[J].陕西医学杂志,2019,48(3):407-409.
[13] Vasilakou D,Karagiannis T,Athanasiadou E,et al.Sodiu mglucose cotransporter 2 inhibitors for type 2 diabetes:a systematic review and meta-analysis[J].Ann Intern Med,2013,159(4):262-274.
[14] ZhaoY,Xu L,Tian D,et al.Effects of sodium-glucose cotransporter 2(SGLT2)inhibitors on serum uric acid level:a meta-analysis of randomized controlled trials[J].Diabetes Obes Metab,2018,20(2):458-462.
[15] Scorsone A,Saura G,Fleres M,et al.Efficacy and renal safety of dapagliflozin in patients with type 2 diabetes mellitus also receiving metformin:a real-life experience[J].J Diabetes Res,2018,2018:8501418.
[16] Merovci A,Solis-Herrera C,Daniele G,et al.Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production[J].J Clin Invest,2014,124(2):509-514.
[17] 朱 路,李华荣.达格列净:中国的首个SGLT2抑制剂[J].实用药物与临床,2017,20(11):1344-1347.
[18] Association AD.Executive summary:standards of medical care in diabetes-2013[J].Diabetes Care,2013,36:4-10.
[19] 刘丽梅,杨 艳.达格列净治疗初治2型糖尿病疗效观察[J].中华实用诊断及治疗杂志,2014,28(9):926-929.
[20] 丁大法,万丽丽.达格列净联合胰岛素对脆性糖尿病血糖波动影响的观察研究[J].中华内分泌代谢,2018,10:844-847.
[21] Kalra S,Jain A,Ved J,et al.Sodium-glucose cotransporter 2 inhibition and health benefits:the robin hood effect[J].Indian J Endocrinol Metab,2016,20(5):725-729.
[22] Bolinder J,Ljunggren O,Kullberg J,et al.Effects of dapagliflozin on body weight,total fat mass,and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin[J].J Clin Endocrinol Metab,2012,97(3):1020-1031.
[23] Bailey CJ,Gross JL,Pieters A,et al.Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin:a randomized,double-blind,placebo-controlled trial[J].Lancet,2010,375(9733):2223-2233.
[24] Gilbert RE.Sodium-glucose linked transporter-2 inhibitors:potential for renoprotection beyond blood glucose lowering[J].Kidney Int,2014,86(4):693-700.
[25] Cherney DZ,Perkins BA,Soleymanlou N,et al.Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus[J].Circulation,2014,129(5):587-597.
[26] Skrtic M,Yang GK,Perkins BA,et al.Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration[J].Diabetologia,2014,57(12):2599-2602.

相似文献/References:

[1]李艳艳,贾 伟△.24h动态心电图在2型糖尿病合并冠心病患者心律诊断中的价值分析[J].陕西医学杂志,2019,(1):61.
[2]郭向东,马 波△.2型糖尿病患者血清胰岛素水平与骨代谢关联研究*[J].陕西医学杂志,2019,(1):77.
　GUO Xiangdong,MA Bo..Association between serum insulin level and bone metabolismin patients with type 2 diabetes mellitus[J].,2019,(11):77.
[3]刘毅龙,陈鹏宇,雷 江,等.SGLT2抑制剂在2型糖尿病合并心血管疾病治疗中的应用研究进展[J].陕西医学杂志,2019,(3):407.
[4]姚爱红.利拉鲁肽治疗2型糖尿病效果及对患者血脂、颈动脉内膜中层厚度的影响[J].陕西医学杂志,2019,(4):518.
　YAO Aihong..Effect of liraglutide on type 2 diabetes mellitus in patients with blood lipids and carotid intimamedia thickness[J].,2019,(11):518.
[5]李忆琴,吴礼凤,余晓君,等.中年2型糖尿病患者病程和HbA1c水平与认知功能相关性研究*[J].陕西医学杂志,2019,(6):722.
[6]徐 琳,贾睿博△,宋民喜,等.颗粒蛋白前体与糖尿病肾病关系探讨*[J].陕西医学杂志,2019,(8):1024.
[7]王荣锋,郁 昊,蒋新建.老年糖尿病患者血清25羟维生素D水平与骨质疏松相关性研究[J].陕西医学杂志,2019,(8):1032.
　WANG Rongfeng,YU Hao,JIANG Xinjian..The relationship between serum 25 hydroxy vitamin D and osteoporosis in elderly diabetic patients[J].,2019,(11):1032.
[8]王 荣,贾爱华,刘新艳 ,等.IGF1及其相关性因素对2型糖尿病并发骨质疏松的影响研究[J].陕西医学杂志,2019,(9):1163.
　WANG Rong,JIA Aihua,LIU Xinyan,et al.The effect of IGF1 and its related factors in type 2 diabetes complicated with osteoporosis[J].,2019,(11):1163.
[9]贾睿博,徐 琳△.2型糖尿病患者下肢血管病变相关危险因素调查研究[J].陕西医学杂志,2019,(11):1567.
[10]孟 涛,刘锦波,王纪科,等.输尿管硬镜钬激光碎石与后腹腔镜上段输尿管切开取石治疗输尿管结石疗效对比研究*[J].陕西医学杂志,2020,49(2):162.
　MENG Tao,LIU Jinbo,WANG Jike,et al.Analysis of efficacy of holmium laser ureteroscopic lithotripsy and retroperitoneal laparoscopic ureterolithotomy on ureteral calculi[J].,2020,49(11):162.

更新日期/Last Update: 2020-11-05